Perspective: rethinking therapeutic strategies in oncology
- PMID: 38269024
- PMCID: PMC10805859
- DOI: 10.3389/fonc.2023.1335987
Perspective: rethinking therapeutic strategies in oncology
Abstract
Immuno-oncology has revolutionized cancer care, drug development, the design of clinical trials, standard treatment paradigms, and the evaluation of response to therapy. These are all areas, however, that have not fully incorporated principles of tumor immunology. Insufficient emphasis is put on the effect drugs have on the immune system, and specifically, the impact that multiple lines of therapy can have on the functioning of the immune system, hindering a robust anti-tumor immune response. A paradigm shift in how we approach the development of novel immunotherapeutic agents is necessary to facilitate the effective improvements in patient outcomes.
Keywords: immuno-oncology; immunosuppression; oncology clinical trials; response evaluation; tumor microenvironment.
Copyright © 2024 Patz, Gottlin and Simon.
Conflict of interest statement
EP is a Founder, Board Member, and the CEO of Grid Therapeutics, LLC. EG is a Founder of Grid Therapeutics, LLC. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
LinkOut - more resources
Full Text Sources
